ARTICLE | Strategy
mAbs are icing on the cake
Antibody deal with Abbott boosts Biotest while it focuses on plasma proteins
July 18, 2011 7:00 AM UTC
Biotest AG has returned to its roots in plasma proteins. After selling off its tools and diagnostics businesses, the company is looking to grow by increasing its plasma protein product offerings and expanding its global presence. Along the way, it plans to opportunistically outlicense a small portfolio of mAbs after advancing them through Phase II testing.
Biotest did its first such deal last month by partnering its BT-061 with Abbott Laboratories for $85 million up front...